Journal of Jilin University(Medicine Edition) ›› 2026, Vol. 52 ›› Issue (1): 272-280.doi: 10.13481/j.1671-587X.20260130
• Review • Previous Articles Next Articles
Received:2025-06-25
Accepted:2025-09-14
Online:2026-01-28
Published:2026-02-25
Contact:
Yunqian LI
E-mail:yunqian@jlu.edu.cn
CLC Number:
Dongxin JIANG, Yunqian LI. Research progress in clinical diagnosis and treatment of oligodendroglioma[J].Journal of Jilin University(Medicine Edition), 2026, 52(1): 272-280.
| [1] | MUBARAK F, KHANDWALA K, SHAMIM S M, et al. Multifocal oligodendroglioma with callosal and brainstem involvement[J]. Surg Neurol Int, 2022, 13: 442. |
| [2] | 赵雅娴, 夏 蕾, 刘 慧, 等. 44例少突胶质细胞瘤的临床病理观察[J]. 临床神经外科杂志, 2023, 20(6): 677-681, 685. |
| [3] | BYEON Y, LEE C, JEON J, et al. Long-term outcomes of CNS WHO grade 2 oligodendroglioma in adult patients: a single-institution experience[J]. Discov Oncol, 2024, 15(1): 268. |
| [4] | 杨晓玲, 李茂进, 谢宝君, 等. 髓母细胞瘤放疗后继发颅内少突胶质细胞瘤一例[J]. 中华放射医学与防护杂志, 2005, 25(4): 364. |
| [5] | MALHOTRA K, DAGLI M M, GUJRAL J, et al. Global and gender equity in oligodendroglioma research: a comprehensive bibliometric analysis following the COVID-19 pandemic[J]. Cureus, 2023, 15(12): e51161. |
| [6] | CAIRNCROSS G, WANG M H, SHAW E, et al. Phase Ⅲ trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402[J]. J Clin Oncol, 2013, 31(3): 337-343. |
| [7] | DE JESÚS MATEO-NOUEL E, MONDRAGÓN-SOTO M G, NICOLÁS-CRUZ C F, et al. Efficient detection of oligodendroglioma with 1p/19q codeletion mutation via methionine PET imaging: a promising diagnostic approach[J]. Cureus, 2025, 17(1): e77826. |
| [8] | 郑丽远, 徐文中, 任 飞, 等. CT与MRI扫描在脑胶质瘤术前诊断中的应用效果分析[J]. 中国CT和MRI杂志, 2024, 22(2): 11-13. |
| [9] | TOADER C, EVA L, COSTEA D, et al. Low-grade gliomas: histological subtypes, molecular mechanisms, and treatment strategies[J]. Brain Sci, 2023, 13(12): 1700. |
| [10] | 王 龙, 牛 晨, 武建利, 等. MRI定性及定量检测在少突胶质细胞瘤分级诊断中的应用价值[J]. 医学影像学杂志, 2025, 35(5): 1-5. |
| [11] | 董文洁, 刘显旺, 韩 涛, 等. MRI征象联合ADC值对节细胞胶质瘤与少突胶质细胞瘤的鉴别诊断[J]. 中国中西医结合影像学杂志, 2025, 23(2): 197-202. |
| [12] | NATSUMEDA M, MATSUZAWA H, WATANABE M, et al. SWI by 7T MR imaging for the microscopic imaging diagnosis of astrocytic and oligodendroglial tumors[J]. Am J Neuroradiol, 2022, 43(11): 1575-1581. |
| [13] | KIKUCHI K, TOGAO O, YAMASHITA K, et al. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted[J]. Neuroradiology, 2024, 66(3): 333-341. |
| [14] | VAN LENT D I, VAN BAARSEN K M, SNIJDERS T J, et al. Radiological differences between subtypes of WHO 2016 grade Ⅱ-Ⅲ gliomas: a systematic review and meta-analysis[J]. Neurooncol Adv, 2020, 2(1): vdaa044. |
| [15] | RINCON-TORROELLA J, RAKOVEC M, MATERI J, et al. Current and future frontiers of molecularly defined oligodendrogliomas[J]. Front Oncol, 2022, 12: 934426. |
| [16] | 李林耘, 李宗芳, 苏国苗, 等. 对成人1p/19q未共缺失的“少突胶质细胞瘤” 的临床病理及分子学分析[J]. 昆明医科大学学报, 2024, 45(8): 7-16. |
| [17] | 王 伟, 张 斌. 少突胶质细胞瘤的诊断和分子标记物研究进展[J]. 中华神经外科疾病研究杂志, 2009, 8(4): 374-375. |
| [18] | RAUTAJOKI K J, JAATINEN S, TIIHONEN A M, et al. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas[J]. Sci Rep, 2022, 12: 14083. |
| [19] | STEPKA J, DOTKA M, KOSIŃSKI M, et al. The role of systemic therapies in the treatment of grades 1-4 gliomas[J]. Cureus, 2024, 16(9): e70532. |
| [20] | WONGSURAWAT T, JENJAROENPUN P, ANEKWIANG P, et al. Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas[J]. Brain Pathol, 2024, 34(1): e13203. |
| [21] | JIANG K, KALLURI A, ODONKOR M, et al. Trends in the management of oligodendrogliomas: a multinational and multidisciplinary survey study[J]. World Neurosurg, 2025, 196: 123716. |
| [22] | 周跃飞, 薛 文, 贾鹏飞, 等. 扩大经鼻内镜手术切除鞍结节脑膜瘤临床应用和分析[J]. 中华神经外科疾病研究杂志, 2024, 18(5): 30-34. |
| [23] | 杨佳, 刘雪松. 3D外视镜辅助经远外侧入路治疗枕骨大孔区腹侧脑膜瘤疗效分析[C]//第十八届中国医师协会神经外科医师年会摘要集-颅底外科.广州: 中山大学附属第一医院, 2024: 36. |
| [24] | 何振强, 钟 升, 杜晓京, 等. 脑胶质瘤治疗研究进展[J]. 中国微侵袭神经外科杂志, 2024, 28(5): 303-316. |
| [25] | HIDANO A, SUGII N, ISHIKAWA E. Newly emerged T2 high-signal intensity area mimicking oligodendroglioma expansion on intraoperative magnetic resonance imaging: a case report[J]. Radiol Case Rep, 2024, 19(11): 5038-5043. |
| [26] | 王跃龙, 吴安华, 屈 延, 等. 复杂难治性颅底肿瘤的精准治疗进展[J]. 临床神经外科杂志, 2025, 22(1): 99-105. |
| [27] | VAZ-SALGADO M Á, GARCÍA B C, PÉREZ I F, et al. SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)[J]. Clin Transl Oncol, 2024, 26(11): 2856-2865. |
| [28] | MITCHELL D, SHIREMAN J M, DEY M. Surgical neuro-oncology[J]. Neurol Clin, 2022, 40(2): 437-453. |
| [29] | 白 杰, 武文元, 马庆海. 儿童颅内巨大钙化肿瘤1例[J]. 中国临床神经外科杂志, 2010, 15(4): 254-255. |
| [30] | ANNAKIB S, RIGAU V, DARLIX A, et al. Bevacizumab in recurrent WHO grades Ⅱ-Ⅲ glioma[J]. Front Oncol, 2023, 13: 1212714. |
| [31] | SHAGHAGHIAN E, PARK D J, YOO K H, et al. CyberKnife radiosurgery for extracranial metastases of oligodendroglioma: a clinical case report[J]. Cureus, 2023, 15(12): e51035. |
| [32] | HADDAD A F, YOUNG J S, OH J Y, et al. The immunology of low-grade gliomas[J]. Neurosurg Focus, 2022, 52(2): E2. |
| [33] | 曹俊如, 张俊丽, 张瑶瑶, 等. 脑胶质瘤治疗方法研究进展[J]. 医药前沿, 2025, 15(1): 43-48. |
| [34] | CHELLIAH S S, PAUL E A L, KAMARUDIN M N A, et al. Challenges and perspectives of standard therapy and drug development in high-grade gliomas[J]. Molecules, 2021, 26(4): 1169. |
| [35] | 祝自虹, 王 惠, 尹 勇. 低级别脑胶质瘤放射治疗进展[J]. 中华肿瘤防治杂志, 2022, 29(6): 381-386. |
| [36] | QIU X X, GAO J, HU J Y, et al. Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from Shanghai proton and heavy ion center[J]. J Neurooncol, 2023, 162(3): 503-514. |
| [37] | KESSLER T, ITO J, WICK W, et al. Conventional and emerging treatments of astrocytomas and oligodendrogliomas[J]. J Neuro Oncol, 2023, 162(3): 471-478. |
| [38] | 郭鹏航, 谢 东, 赵全堂, 等. 低级别胶质瘤临床治疗进展[J]. 中国神经精神疾病杂志, 2024, 50(5): 310-314. |
| [39] | GOFF K M, ZHENG C Q, ALONSO-BASANTA M. Proton radiotherapy for glioma and glioblastoma[J]. Chin Clin Oncol, 2022, 11(6): 46. |
| [40] | NITSCH L, HERRLINGER U, SCHÄFER N. Detection of vincristine-induced neuropathy in patients with oligodendroglioma[J]. Neurooncol Pract, 2022, 9(5): 456-457. |
| [41] | 吴小延, 王苏杰, 王 芳, 等. IDH突变和1p/19q共缺失型少突胶质细胞瘤临床病理特征和预后分析[J]. 肿瘤防治研究, 2024, 51(3): 178-184. |
| [42] | KROLICKI L, KUNIKOWSKA J, CORDIER D, et al. Long-term tumor control following targeted alpha therapy (TAT) of low-grade gliomas (LGGs): a new treatment paradigm?[J]. Int J Mol Sci, 2023, 24(21): 15701. |
| [43] | CHEN S N, WANG Z Y, ZHOU D S, et al. Case report: ISL2 is involved in malignant transformation in a patient with multiple relapsed oligodendroglioma[J]. Front Oncol, 2022, 12: 969191. |
| [44] | BATSIOS G, TAGLANG C, GILLESPIE A M, et al. Imaging telomerase reverse transcriptase expression in oligodendrogliomas using hyperpolarized δ-[1-(13)C]-gluconolactone[J]. Neurooncol Adv, 2023, 5(1): vdad092. |
| [45] | 程孟祺, 秦英刚, 姜菊玲, 等. 中医药治疗脑胶质瘤临床研究进展[J]. 辽宁中医药大学学报, 2020, 22(12): 147-151. |
| [46] | 刘盛男, 樊永平, 仝延萍, 等. 扶正祛邪法治疗脑胶质瘤临床经验[J]. 中华中医药杂志, 2022, 37(11): 6531-6534. |
| [47] | 周敏华, 刘忠达, 季兴祖, 等. 刘忠达辨治恶性脑胶质瘤经验[J]. 浙江中西医结合杂志, 2023, 33(11): 1036-1038. |
| [48] | BRAIDOTTI S, CURCI D, ZAMPIERI D, et al. Iron bioavailability in the extracellular environment is more relevant than the intracellular one in viability and gene expression: a lesson from oligodendroglioma cells[J]. Biomedicines, 2023, 11(11): 2940. |
| [1] | Lei TANG,Peinan LIN,Ling ZHANG,Haiyan XU,Fengchun ZHANG. Chemotherapy efficacy and plasma drug concentration changes in patient with limited-stage small cell lung cancer complicated with uremia: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1687-1694. |
| [2] | Teng LIU,Ning ZHANG,Mingyuan HE,Guanghui CHENG. Research progress in treatment principles for endometrial cancer and its postoperative and postoperative recurrent radiotherapy [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1747-1754. |
| [3] | Jia YANG,Lingling TONG,Jinshu MA,Huafeng GENG. Misdiagnosis of ovarian sclerosing stromal tumor as malignant tumor: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1115-1120. |
| [4] | Ziru ZHOU,Mengfei SUN,Huakun ZHANG,Shuyan SUN,Qi SUN,Feng LI,Yunzhao CHEN,Jie YU,Yuwen CAO,Xiaobin CUI. Expression of Rh family C glycoprotein in esophageal squamous carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1019-1027. |
| [5] | Junlin CHEN,Zhaowei GAO,Ke DONG,Ziyue LI. Clinical value of serum adenosine deaminase 2 activity in diagnosis and severity evaluation of systemic lupus erythematosus [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1094-1099. |
| [6] | Luyao WANG,Chenxi ZHAO,Wanze ZHANG,Linlin LIU. Second primary tracheal adenoid cystic carcinoma:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 215-221. |
| [7] | Shimeng LI,Xin QI,Sitong LIN,Xiangwen SAN,Ling JIN,Sitong ZHANG. Reactive plasmacytosis caused by methimazole in patients with Graves’ disease: One case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1414-1419. |
| [8] | Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015. |
| [9] | Ying ZHANG,Xianxun JIANG,Zhaohui WAN. Enhancement effect of TPX2 gene silencing on chemosensitivity of bladder cancer cell line T24/DDP to cisplatin and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 346-354. |
| [10] | Yulu QUAN,Pingping ZHANG,Yan LUO,Jing HUO,Xiaoping YU,Yanmei SUN,Yali LI. Aortic stenosis of fetus caused by chimeric Y-chromosome isobaric double-adherent granules:A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 260-264. |
| [11] | Guangcai WAN,Ting LI,Weixiu SUN,Xiuyan YU. Modification and effect evaluation of pretreatment methods for rapid detection specimens of SARS-CoV-2 [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1649-1654. |
| [12] | Zhirui CHUAN,Hongying YANG,Zhiyao LI,Dong CHEN,Huijing NI,Xiaokai LU,Haitao CHEN,Xiaomao LUO. Effect of shear wave elastography on differential diagnosis of benign and malignant breast non-mass lesions [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1625-1634. |
| [13] | Wenli JIANG,Lin ZHANG,Junyao LI,Mingyu XU,Jie ZHANG,Chunling DONG. Targeted therapy of osimertinib combined with savolitinib in NSCLC with EGFR-TKI resistance complicated with MET amplification: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2023, 49(3): 782-788. |
| [14] | Dehong ZHANG,Mingzhu ZHENG,Jiaqiu LI,Zhong LU. Bioinformatics analysis based on expressions of MSR1 mRNA and protein in pan-cancer tissue and its significance [J]. Journal of Jilin University(Medicine Edition), 2023, 49(2): 425-439. |
| [15] | Xiaohui WU,Fan YANG,Xinru GUO,Ke YUAN,Zongyi MA,Ting LIAN,Rajiv Kumar JHA. Effect of Orlistat combined with EZH2 inhibitor GSK126 on lipid metabolism reprogramming in pancreatic cancer cells [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 55-66. |
|
||
